Indefinite Delivery Contract SPE2DR25D9915

The key details of this federal Indefinite Delivery Contract (IDC) are as follows:

The Defense Logistics Agency (DLA) awarded a single-award IDC to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide a comprehensive range of pharmaceutical products and medical supplies to support the recurring medical needs of military healthcare facilities and veterans' medical centers nationwide. The $499,999,999 IDC, valid through November 2026, enables DLA to issue firm fixed-price delivery orders for branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables across various product categories such as injections, tablets, creams, auto-injectors, and specialty medications.

This IDC was awarded under the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) acquisition, which seeks to establish multiple regional prime vendor contracts to provide worldwide pharmaceutical support to the Department of Defense, United States Coast Guard, and other government agencies. The unrestricted, fully competitive solicitation is expected to be issued in March 2024 with a 45-day response period, and will be awarded on a lowest price technically acceptable basis, potentially using a reverse auction process to determine final distribution fees.